R E O'Cearbhaill - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

R E O'Cearbhaill

Showing results (1-10 of 5) with videos related to

Pageof 1

Sort By:

Cancer Treatment Reviews|June 3, 2021

Exploiting somatic alterations as therapeutic targets in advanced and metastatic cervical cancerF J Crowley, R E O'Cearbhaill, D C Collins

Gynecologic Oncology|May 21, 2022

Immunotherapy toxicities: An SGO clinical practice statementR E O'Cearbhaill, L Clark, R N Eskander, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2017

Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013A Oseledchyk, M M Leitao, J Konner, et al.

Gynecologic Oncology|June 14, 2023

Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO)B Pothuri, S V Blank, T K Myers, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2024

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trialB J Monk, M P Barretina-Ginesta, B Pothuri, et al.

Pageof 1

Search research articles

Showing results (1-10 of 5) with videos related to

Sort By:

Pageof 1

Cancer Treatment Reviews|June 3, 2021

Exploiting somatic alterations as therapeutic targets in advanced and metastatic cervical cancerF J Crowley, R E O'Cearbhaill, D C Collins

Gynecologic Oncology|May 21, 2022

Immunotherapy toxicities: An SGO clinical practice statementR E O'Cearbhaill, L Clark, R N Eskander, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2017

Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013A Oseledchyk, M M Leitao, J Konner, et al.

Gynecologic Oncology|June 14, 2023

Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO)B Pothuri, S V Blank, T K Myers, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2024

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trialB J Monk, M P Barretina-Ginesta, B Pothuri, et al.

Pageof 1